Nonalcoholic Steatohepatitis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Nonalcoholic Steatohepatitis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Nonalcoholic steatohepatitis treatment (NASH) is a syndrome which causes liver damage in non-alcoholic patients. It develops most often in patients with at least one factors such as dyslipidemia, obesity, and glucose intolerance. NASH pathogenesis is not clearly understood however is considered to be linked with insulin resistance. It is diagnosed with the help of blood tests, imaging tests, and sometimes liver biopsy. Treatment of the NASH includes elimination of causes and risk factors such as reducing fat level in the body. NASH is also considered to be one of the chief causes of cirrhosis which can lead to complete liver failure.
Market Dynamics
Obesity, high blood pressure and cholesterol level, type 2 diabetes and metabolic syndrome are the major cause of the NASH onset. Increasing prevalence of these conditions worldwide is expected to drive the global nonalcoholic steatohepatitis treatment market growth during the forecast period. According to the International Diabetes Federation 2021 data, approximately 425 million people were suffering from diabetes in the world and 82 million cases were in the South East Asia region which is expected to reach 151 million by 2045.
However, diagnosis of the NASH can be difficult to catch in an early stage and can take years before patients show any sort of symptoms which is a major factor hampering the nonalcoholic steatohepatitis treatment market.
Key features of the study:
This report provides in-depth analysis of the nonalcoholic steatohepatitis treatment market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global nonalcoholic steatohepatitis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global nonalcoholic steatohepatitis treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for nonalcoholic steatohepatitis treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Global Nonalcoholic Steatohepatitis Treatment Market, By Drug:
Cenicriviroc
Elafibranor
Ocaliva (Obeticholic Acid)
Selonsertib
Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Nonalcoholic Steatohepatitis Treatment Market, By Region:
North America
By Country:
U.S.
Canada
By Drug:
Cenicriviroc
Elafibranor
Ocaliva (Obeticholic Acid)
Selonsertib
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug:
Cenicriviroc
Elafibranor
Ocaliva (Obeticholic Acid)
Selonsertib
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug:
Cenicriviroc
Elafibranor
Ocaliva (Obeticholic Acid)
Selonsertib
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug:
Cenicriviroc
Elafibranor
Ocaliva (Obeticholic Acid)
Selonsertib
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug:
Cenicriviroc
Elafibranor
Ocaliva (Obeticholic Acid)
Selonsertib
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Africa
By Country:
South Africa
Central Africa
North Africa
By Drug:
Cenicriviroc
Elafibranor
Ocaliva (Obeticholic Acid)
Selonsertib
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Company Profiles
AstraZeneca Plc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Conatus Pharmaceuticals
Enzo Biochem, Inc.
GENFIT SA
Galmed Pharmaceuticals Ltd.
Gilead Science
Immuron Ltd.
Intercepts Pharmaceuticals
Novo Nordisk
Raptor Pharmaceutical Corporation
Tobira Therapeutics, Inc.
“*” marked represents similar segmentation in other categories in the respective section.